Cellectis SA
https://www.cellectis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cellectis SA
Can AstraZeneca Sustain Sector-Beating Growth? Its Buying Spree Could Help
AstraZeneca has maintained sector-beating growth for five years, but is looking to a new wave of bolt-on acquisitions and licensing deals to sustain that trajectory beyond 2030.
AstraZeneca Likes What Chinese Innovation Has To Offer
Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip.
Finance Watch: CARGO Gets A Lukewarm Reception After Stock Market Debut
Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.
AstraZeneca CEO Soriot On Obesity, Gene Therapy And More
CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
- Other Names / Subsidiaries
-
- Calyxt
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice